Crypto: Ripple Prepares a Massive Buyback of 750 Million Dollars
The crypto market has been plummeting for weeks, dragging Bitcoin and other tokens down with it. However, Ripple is not just standing by waiting for better days. Brad Garlinghouse’s company is fighting back with a major financial operation. While industry giants are sneezing, it is preparing a massive stock buyback. A bold way to show who still holds the helm when the storm rages.
In brief
- Ripple launches a 750 million dollar stock buyback valuing the company at 50 billion.
- This valuation marks a 25% increase despite a crypto market in freefall.
- The company spent more than 2.5 billion in strategic acquisitions during 2025.
- XRP has fallen 62% since its peak, but Ripple shows robust financial health.
Buyback at 750 Million: Ripple’s Bold Bet in the Midst of a Crypto Storm
First, let’s look at the dizzying figure. Ripple announces a 750 million dollar stock buyback from its employees and investors. This operation values the company at 50 billion, 25% more than at its November fundraising.
Yet, the context seems anything but favorable. Bitcoin has lost 40% since October. XRP, Ripple’s historic token, has collapsed 62% from its peak in July.
The firm doesn’t seem affected by this widespread drop. It’s sending a strong signal to the entire market. The management believes in its value more than ever. Employees had already shown their trust by refusing to sell their shares at 40 billion.
Today, Ripple offers them 25% more, a rare sign of recognition.
Ripple’s Secret Strategy: Buying Everything That Moves to Dominate Crypto Finance
How can Ripple afford such luxury while the sector is bleeding? The answer comes down to one word: acquisitions. The company spent over 2.5 billion dollars in 2025 acquiring strategic companies.
Hidden Road, a prime broker, was purchased for 1.25 billion. GTreasury, a treasury specialist, cost 1 billion. Rail and Palisade complemented the offer on stablecoins and asset custody.
In 2026, Ripple continues its momentum by buying BC Payments in Australia to secure a local financial license. The company no longer presents itself as “the XRP company.” It is patiently building an empire of services for institutions.
Its stablecoin, RLUSD, exceeds one billion in market cap in less than a year. It claims 100 billion dollars in transactions processed, as proudly tweeted: “100 billion+ processed. 60+ markets. 51 real-time rails. RLUSD at 1 billion market cap in less than a year“.
The XRP Mystery: How the Token Collapses While Ripple Thrives
Here is the paradox that intrigues the entire crypto sphere. XRP, the token created by Ripple, has lost 62% since its July high. It drags at 1.3 dollars, far from the peaks reached. Yet, the company displays insolent health.
Brad Garlinghouse, the CEO, repeats that XRP remains the “compass” of the company. He explained recently:
There will be a trillion-dollar crypto company, I do not doubt it for a second. I think Ripple has the opportunity, if we do things right, to be that company.
But actions sometimes speak louder. Ripple is developing RLUSD, its stablecoin, which is slowly cannibalizing XRP’s role. It signs with Mastercard without even mentioning the token.
Is the market beginning to value Ripple independently of XRP? A historic break is playing out before our eyes.
Ripple in numbers: the quiet strength
- 750 million: the amount of the stock buyback launched by the company;
- 50 billion: the new valuation, up 25% in four months;
- 2.5 billion: acquisition spending during the year 2025;
- 100 billion: the volume of transactions processed by Ripple Payments;
- 1.37 dollars: the current price of XRP, down 62% since its peak.
One year ago, Ripple could have ridden a wave of IPOs in a favorable context. Markets were strong, crypto was euphoric. Yet, Garlinghouse chose to stay private. Today, this choice makes perfect sense. While public companies face the fury of the markets, Ripple quietly moves forward, buying back its shares away from prying eyes.
Maximize your Cointribune experience with our "Read to Earn" program! For every article you read, earn points and access exclusive rewards. Sign up now and start earning benefits.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify
In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Crypto prices
More
